GlassScriptPhysician profile
Paul A Jacobs
NPI 1841295243
$2,882.91
in general payments reported to CMS, 2019-2025
32 companies · $609 in 2025
The $609 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $589 · 2020: $148 · 2021: $36.91 · 2022: $644 · 2023: $365 · 2024: $491 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,465.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $470.76 | 2019-2023 | |
| Gynesonics, INC. | $324.09 | 2022-2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Astellas Pharma US INC | $237.50 | 2023-2025 | Veozah |
| Exeltis, USA INC. | $175.85 | 2019-2025 | Slynd |
| Meditrina | $175.62 | 2021-2025 | |
| Hologic Sales and Service, LLC | $172.43 | 2023-2025 | Fluent Fluid Management System, Aptima, Thinprep 2000 Processor |
| Avion Pharmaceuticals | $154.62 | 2021-2022 | |
| Daiichi Sankyo INC. | $142.98 | 2019-2025 | Injectafer |
| Avanos Medical | $132.87 | 2019 | |
| Sage Therapeutics, LLC | $103.57 | 2024-2025 | Zurzuvae |
| Boston Scientific Corporation | $93.11 | 2019 | |
| Organon LLC | $65.95 | 2024 | |
| Channel Medsystems, INC. | $64.80 | 2023 | |
| Ethicon US, LLC | $61.62 | 2025 | Vistaseal, Stratafix, Ethicon |
| Bayer Healthcare Pharmaceuticals INC. | $57.94 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $53.03 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $50.06 | 2019-2024 | Gardasil, Gardasil 9 |
| Millicent US INC | $41.61 | 2025 | Femlyv |
| Pfizer INC. | $38.19 | 2022-2023 | |
| Innovation Technologies INC | $32.54 | 2024 | Irrisept |
| Shield Therapeutics INC | $32.01 | 2023-2024 | Accrufer |
| Amag Pharmaceuticals, INC. | $28.87 | 2019 | |
| Sumitomo Pharma America, INC. | $23.68 | 2023 | Myfembree |
| Therapeuticsmd, INC. | $21.17 | 2022 | |
| Agile Therapeutics, INC. | $19.93 | 2022 | |
| Baxter Healthcare | $18.24 | 2024 | Perclot |
| Grifols USA, LLC | $18.20 | 2025 | Thrombate III |
| Novo Nordisk INC | $17.25 | 2024 | Wegovy |
| Caldera Medical, INC | $17.03 | 2023 | Desara |
| Mission Pharmacal Company | $13.44 | 2019 | |
| Duchesnay USA Incorporated | $12.19 | 2019 | |
| Minerva Surgical, INC | $11.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.